Hepatitis B and C reactivation with tumor necrosis factor inhibitors: Synopsis and interpretation of screening and prophylaxis recommendations

Inbal Fuchs, Mahmoud Abu-Shakra, Emanuel Sikuler

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

Information on reactivation of chronic viral hepatitis infection in patients who are candidates for tumor necrosis factor alpha inhibitors (TNFi) is in a constant state of flux. We retrieved the most updated guidelines (in English) of prominent rheumatological and gastroenterological professional societies for the management of chronic hepatitis B (HBV) and hepatitis C virus (HCV) infection in the context of treatment with TNFi. Subsequently, the major areas of uncertainty and absence of consensus in the guidelines were located and a secondary search for additional studies addressing those areas was performed. Based on our search we formulated a personal interpretation applicable to health care settings with virological laboratories capable of performing viral load measurements, and health systems that can support use of potent nucleoside/tide analogues in well-defined patient populations.

Original languageEnglish
Pages (from-to)303-307
Number of pages5
JournalIsrael Medical Association Journal
Volume15
Issue number6
StatePublished - 1 Jun 2013
Externally publishedYes

Keywords

  • Hepatitis B virus (HBV)
  • Hepatitis C virus (HCV)
  • Reactivation
  • Tumor necrosis-alpha inhibitors (TNFi)

ASJC Scopus subject areas

  • Medicine (all)

Fingerprint

Dive into the research topics of 'Hepatitis B and C reactivation with tumor necrosis factor inhibitors: Synopsis and interpretation of screening and prophylaxis recommendations'. Together they form a unique fingerprint.

Cite this